Developing guidelines for venous thromboembolism for the National Institute for Clinical Excellence: Involvement of the orthopaedic surgical panel

Journal of Bone and Joint Surgery - Series B

Volumn 92, Issue 5, 2010, Pages 611-616

  Treasure, T ^a,b   Chong, L Y ^a,c   Sharpin, C ^a,c   Wonderling, D ^a,c   Head, K ^a,c   Hill, J ^a,c  

^a Centre for Acute and Chronic Conditions   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; DABIGATRAN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN;

BLEEDING; CLINICAL TRIAL; COMPRESSION GARMENT; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG MEGADOSE; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; MEDICAL PRACTICE; MEDICAL SPECIALIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK FACTOR; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; HEMORRHAGE; HUMANS; META-ANALYSIS AS TOPIC; ORTHOPEDICS; PERSONNEL SELECTION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SAFETY MANAGEMENT; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 77951792822     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.92B5.24448     Document Type: Review

References (16)

1. No authors listed. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients undergoing surgery. National Institute for Health and Clinical Excellence 2007 http:// www.nice.org.uk/CG46 (date last accessed 2 February 2009).
2. Hill J, Treasure T. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients having surgery: summary of NICE guidance. BMJ 2007;334:1053-1054 (Pubitemid 46808456)
3. Sharrock NE, Gonzalez Della Valle A, Go G, Lyman S, Salvati EA. Potent anti-coagulants are associated with a higher all-cause mortality rate after hip and knee arthroplasty. Clin Orthop 2008;466:714-721 (Pubitemid 351903839)
4. Geerts WH, Bergvist D, Pineo GF,et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 Suppl):381-453.
5. Haas SB, Barrack RL, Westrich G, Lachiewicz PF. Venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg [Am] 2008;90-A:2764-2780
6. Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopaedic Surgeons and American Collee of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 2009;135:513-520
7. Hirsh J, Guyatt G. Clinical experts or methodologists to write clinical guidelines? Lancet 2009;374:273-275
8. No authors lised. Venous thromboembolism: reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. Methods Evidence & Guidance. London: National Clinical Guidance Centre - Acute and Chronic Conditions. 2010:CG92. http://www.nice.org. uk/nicemedia/pdf/ CG92FullGuideline.pdf (date last accessed, 17 March 2010).
9. No authors listed. National Institute for Health and Clinical Excellence. The Guidelines Manual. http://www. nice.org.uk/aboutnice/howwework/ developingniceclinicalguidelines/ clinicalguidelinedevelopmentmethods/ theguidelinesmanual2007/ the-guidelines-manual-2007.jsp (date last accessed 1 February 2009).
10. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-3124 (Pubitemid 39334902)
11. No authors listed. House of Commons Health Select Committee. The prevention of thromboembolism in hospitalised patients: second report of session 2004-2005. House of Commons Health Committee 2005. http://www.publications. parliament.uk/pa/ cm200405/cmselect/cmhealth/99/99.pdf (date last accessed 1 February 2009).
12. Cohen AT, Agnelli G, Anderson FA, et al. Venousthromboembolism (VTE) in Europe: the number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98:756-764 (Pubitemid 47555066)
13. Hunt BJ. Awareness and politics of venous thromboembolism in the United Kingdom. Arterioscler Thromb Vasc Biol 2008;28:398-399
14. Eikelboom JW, Quinlan DJ, O'Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009;120:2006-2011
15. Choudhry NK, Anderson GM, Laupacis A, et al. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006;332:141-145 (Pubitemid 43139397)
16. No authors listed, National Joint Registry. National Joint Registry 2010. http:// www.njrcentre.org.uk/njrcentre/default.aspx (date last accessed 1 February 2009).